APO Research
Talk to an analyst

APO RESEARCH · REPORT

PDGFRα/β Multikinase Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global PDGFRα/β Multikinase Antagonists Market Analysis and Forecast 2026-2032

29 December 2025199 pages

Choose your research edition.

Industry ResearchPDGFRα/β Multikinase Antagonists Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal PDGFRα/β Multikinase Antagonists Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal PDGFRα/β Multikinase Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PDGFRα/β Multikinase Antagonists Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal PDGFRα/β Multikinase Antagonists Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global PDGFRα/β Multikinase Antagonists market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for PDGFRα/β Multikinase Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for PDGFRα/β Multikinase Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for PDGFRα/β Multikinase Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for PDGFRα/β Multikinase Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of PDGFRα/β Multikinase Antagonists include Il-Yang Pharmaceutical, Takeda, Eisai, Novartis, Eli Lilly, Pfizer, GSK, Boehringer Ingelheim and Bayer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for PDGFRα/β Multikinase Antagonists, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of PDGFRα/β Multikinase Antagonists, also provides the revenue of main regions and countries. Of the upcoming market potential for PDGFRα/β Multikinase Antagonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the PDGFRα/β Multikinase Antagonists revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global PDGFRα/β Multikinase Antagonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for PDGFRα/β Multikinase Antagonists revenue, projected growth trends, production technology, application and end-user industry.

PDGFRα/β Multikinase Antagonists Segment by Company

Il-Yang Pharmaceutical

Takeda

Eisai

Novartis

Eli Lilly

Pfizer

GSK

Boehringer Ingelheim

Bayer

Bristol-Myers Squibb

PDGFRα/β Multikinase Antagonists Segment by Type

Capsules

Tablets

Others

PDGFRα/β Multikinase Antagonists Segment by Application

Hospitals

Clinics

PDGFRα/β Multikinase Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PDGFRα/β Multikinase Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PDGFRα/β Multikinase Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PDGFRα/β Multikinase Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of PDGFRα/β Multikinase Antagonists in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of PDGFRα/β Multikinase Antagonists company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PDGFRα/β Multikinase Antagonists revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global PDGFRα/β Multikinase Antagonists Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Capsules Major Player Table 3. Tablets Major Player Table 4. Others Major Player Table 5. Global PDGFRα/β Multikinase Antagonists Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Player Table 7. Clinics Major Player Table 8. PDGFRα/β Multikinase Antagonists Industry Trends Table 9. PDGFRα/β Multikinase Antagonists Industry Drivers Table 10. PDGFRα/β Multikinase Antagonists Industry Opportunities and Challenges Table 11. PDGFRα/β Multikinase Antagonists Industry Restraints Table 12. Global PDGFRα/β Multikinase Antagonists Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global PDGFRα/β Multikinase Antagonists Market Size by Region (2021-2026) & (US$ Million) Table 14. Global PDGFRα/β Multikinase Antagonists Market Share by Region (2021-2026) Table 15. Global PDGFRα/β Multikinase Antagonists Market Size by Region (2027-2032) & (US$ Million) Table 16. Global PDGFRα/β Multikinase Antagonists Market Share by Region (2027-2032) Table 17. Global PDGFRα/β Multikinase Antagonists Revenue by Players (US$ Million) & (2021-2026) Table 18. Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Players (2021-2026) Table 19. Global PDGFRα/β Multikinase Antagonists Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global PDGFRα/β Multikinase Antagonists Key Players Headquarters & Area Served Table 21. Global PDGFRα/β Multikinase Antagonists Players, Product Type & Application Table 22. Global PDGFRα/β Multikinase Antagonists Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global PDGFRα/β Multikinase Antagonists by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global PDGFRα/β Multikinase Antagonists Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 27. Global PDGFRα/β Multikinase Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 28. Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Type (2021-2026) Table 29. Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Type (2027-2032) Table 30. Global PDGFRα/β Multikinase Antagonists Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 32. Global PDGFRα/β Multikinase Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 33. Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Application (2021-2026) Table 34. Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Application (2027-2032) Table 35. Il-Yang Pharmaceutical Company Information Table 36. Il-Yang Pharmaceutical Business Overview Table 37. Il-Yang Pharmaceutical PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Il-Yang Pharmaceutical PDGFRα/β Multikinase Antagonists Product Portfolio Table 39. Il-Yang Pharmaceutical Recent Development Table 40. Takeda Company Information Table 41. Takeda Business Overview Table 42. Takeda PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Takeda PDGFRα/β Multikinase Antagonists Product Portfolio Table 44. Takeda Recent Development Table 45. Eisai Company Information Table 46. Eisai Business Overview Table 47. Eisai PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Eisai PDGFRα/β Multikinase Antagonists Product Portfolio Table 49. Eisai Recent Development Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Novartis PDGFRα/β Multikinase Antagonists Product Portfolio Table 54. Novartis Recent Development Table 55. Eli Lilly Company Information Table 56. Eli Lilly Business Overview Table 57. Eli Lilly PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Eli Lilly PDGFRα/β Multikinase Antagonists Product Portfolio Table 59. Eli Lilly Recent Development Table 60. Pfizer Company Information Table 61. Pfizer Business Overview Table 62. Pfizer PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Pfizer PDGFRα/β Multikinase Antagonists Product Portfolio Table 64. Pfizer Recent Development Table 65. GSK Company Information Table 66. GSK Business Overview Table 67. GSK PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. GSK PDGFRα/β Multikinase Antagonists Product Portfolio Table 69. GSK Recent Development Table 70. Boehringer Ingelheim Company Information Table 71. Boehringer Ingelheim Business Overview Table 72. Boehringer Ingelheim PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Boehringer Ingelheim PDGFRα/β Multikinase Antagonists Product Portfolio Table 74. Boehringer Ingelheim Recent Development Table 75. Bayer Company Information Table 76. Bayer Business Overview Table 77. Bayer PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Bayer PDGFRα/β Multikinase Antagonists Product Portfolio Table 79. Bayer Recent Development Table 80. Bristol-Myers Squibb Company Information Table 81. Bristol-Myers Squibb Business Overview Table 82. Bristol-Myers Squibb PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Bristol-Myers Squibb PDGFRα/β Multikinase Antagonists Product Portfolio Table 84. Bristol-Myers Squibb Recent Development Table 85. North America PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 86. North America PDGFRα/β Multikinase Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 87. North America PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 88. North America PDGFRα/β Multikinase Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 89. North America PDGFRα/β Multikinase Antagonists Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America PDGFRα/β Multikinase Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 91. North America PDGFRα/β Multikinase Antagonists Revenue by Country (US$ Million) & (2027-2032) Table 92. Europe PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 93. Europe PDGFRα/β Multikinase Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 94. Europe PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 95. Europe PDGFRα/β Multikinase Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 96. Europe PDGFRα/β Multikinase Antagonists Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe PDGFRα/β Multikinase Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 98. Europe PDGFRα/β Multikinase Antagonists Revenue by Country (US$ Million) & (2027-2032) Table 99. China PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 100. China PDGFRα/β Multikinase Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 101. China PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 102. China PDGFRα/β Multikinase Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 103. Asia PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 104. Asia PDGFRα/β Multikinase Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 105. Asia PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 106. Asia PDGFRα/β Multikinase Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia PDGFRα/β Multikinase Antagonists Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia PDGFRα/β Multikinase Antagonists Revenue by Region (US$ Million) & (2021-2026) Table 109. Asia PDGFRα/β Multikinase Antagonists Revenue by Region (US$ Million) & (2027-2032) Table 110. SAMEA PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 111. SAMEA PDGFRα/β Multikinase Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 112. SAMEA PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 113. SAMEA PDGFRα/β Multikinase Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 114. SAMEA PDGFRα/β Multikinase Antagonists Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. SAMEA PDGFRα/β Multikinase Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 116. SAMEA PDGFRα/β Multikinase Antagonists Revenue by Country (US$ Million) & (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. PDGFRα/β Multikinase Antagonists Image Figure 2. Global PDGFRα/β Multikinase Antagonists Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PDGFRα/β Multikinase Antagonists Market Size Share 2021 VS 2025 VS 2032 Figure 4. Capsules Image Figure 5. Tablets Image Figure 6. Others Image Figure 7. Global PDGFRα/β Multikinase Antagonists Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global PDGFRα/β Multikinase Antagonists Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Global PDGFRα/β Multikinase Antagonists Market Size (US$ Million) & (2021-2032) Figure 12. Global PDGFRα/β Multikinase Antagonists Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global PDGFRα/β Multikinase Antagonists Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global PDGFRα/β Multikinase Antagonists Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global PDGFRα/β Multikinase Antagonists Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global PDGFRα/β Multikinase Antagonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Type (2021-2032) Figure 19. Global PDGFRα/β Multikinase Antagonists Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Application (2021-2032) Figure 22. North America PDGFRα/β Multikinase Antagonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America PDGFRα/β Multikinase Antagonists Revenue Share by Type (2021-2032) Figure 24. North America PDGFRα/β Multikinase Antagonists Revenue Share by Application (2021-2032) Figure 25. North America PDGFRα/β Multikinase Antagonists Revenue Share by Country (2021-2032) Figure 26. United States PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe PDGFRα/β Multikinase Antagonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe PDGFRα/β Multikinase Antagonists Revenue Share by Type (2021-2032) Figure 31. Europe PDGFRα/β Multikinase Antagonists Revenue Share by Application (2021-2032) Figure 32. Europe PDGFRα/β Multikinase Antagonists Revenue Share by Country (2021-2032) Figure 33. Germany PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China PDGFRα/β Multikinase Antagonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China PDGFRα/β Multikinase Antagonists Revenue Share by Type (2021-2032) Figure 43. China PDGFRα/β Multikinase Antagonists Revenue Share by Application (2021-2032) Figure 44. Asia PDGFRα/β Multikinase Antagonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia PDGFRα/β Multikinase Antagonists Revenue Share by Type (2021-2032) Figure 46. Asia PDGFRα/β Multikinase Antagonists Revenue Share by Application (2021-2032) Figure 47. Asia PDGFRα/β Multikinase Antagonists Revenue Share by Region (2021-2032) Figure 48. Japan PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA PDGFRα/β Multikinase Antagonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA PDGFRα/β Multikinase Antagonists Revenue Share by Type (2021-2032) Figure 56. SAMEA PDGFRα/β Multikinase Antagonists Revenue Share by Application (2021-2032) Figure 57. SAMEA PDGFRα/β Multikinase Antagonists Revenue Share by Country (2021-2032) Figure 58. Brazil PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt PDGFRα/β Multikinase Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Capsules
  • Tablets
  • Others
Applications
  • Hospitals
  • Clinics
Companies covered
  • Il-Yang Pharmaceutical
  • Takeda
  • Eisai
  • Novartis
  • Eli Lilly
  • Pfizer
  • GSK
  • Boehringer Ingelheim
  • Bayer
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 PDGFRα/β Multikinase Antagonists Market by Type
  3. 1.2.1 Global PDGFRα/β Multikinase Antagonists Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Capsules
  5. 1.2.3 Tablets
  6. 1.2.4 Others
  7. 1.3 PDGFRα/β Multikinase Antagonists Market by Application
  8. 1.3.1 Global PDGFRα/β Multikinase Antagonists Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 PDGFRα/β Multikinase Antagonists Market Dynamics
  1. 2.1 PDGFRα/β Multikinase Antagonists Industry Trends
  2. 2.2 PDGFRα/β Multikinase Antagonists Industry Drivers
  3. 2.3 PDGFRα/β Multikinase Antagonists Industry Opportunities and Challenges
  4. 2.4 PDGFRα/β Multikinase Antagonists Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global PDGFRα/β Multikinase Antagonists Market Perspective (2021-2032)
  2. 3.2 Global PDGFRα/β Multikinase Antagonists Growth Trends by Region
  3. 3.2.1 Global PDGFRα/β Multikinase Antagonists Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global PDGFRα/β Multikinase Antagonists Market Size by Region (2021-2026)
  5. 3.2.3 Global PDGFRα/β Multikinase Antagonists Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global PDGFRα/β Multikinase Antagonists Revenue by Players
  2. 4.1.1 Global PDGFRα/β Multikinase Antagonists Revenue by Players (2021-2026)
  3. 4.1.2 Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global PDGFRα/β Multikinase Antagonists Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global PDGFRα/β Multikinase Antagonists Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global PDGFRα/β Multikinase Antagonists Key Players Headquarters & Area Served
  7. 4.4 Global PDGFRα/β Multikinase Antagonists Players, Product Type & Application
  8. 4.5 Global PDGFRα/β Multikinase Antagonists Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global PDGFRα/β Multikinase Antagonists Market CR5 and HHI
  11. 4.6.3 2025 PDGFRα/β Multikinase Antagonists Tier 1, Tier 2, and Tier 3
5 PDGFRα/β Multikinase Antagonists Market Size by Type
  1. 5.1 Global PDGFRα/β Multikinase Antagonists Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2032)
  3. 5.3 Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Type (2021-2032)
6 PDGFRα/β Multikinase Antagonists Market Size by Application
  1. 6.1 Global PDGFRα/β Multikinase Antagonists Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2032)
  3. 6.3 Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Il-Yang Pharmaceutical
  2. 7.1.1 Il-Yang Pharmaceutical Company Information
  3. 7.1.2 Il-Yang Pharmaceutical Business Overview
  4. 7.1.3 Il-Yang Pharmaceutical PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Il-Yang Pharmaceutical PDGFRα/β Multikinase Antagonists Product Portfolio
  6. 7.1.5 Il-Yang Pharmaceutical Recent Developments
  7. 7.2 Takeda
  8. 7.2.1 Takeda Company Information
  9. 7.2.2 Takeda Business Overview
  10. 7.2.3 Takeda PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Takeda PDGFRα/β Multikinase Antagonists Product Portfolio
  12. 7.2.5 Takeda Recent Developments
  13. 7.3 Eisai
  14. 7.3.1 Eisai Company Information
  15. 7.3.2 Eisai Business Overview
  16. 7.3.3 Eisai PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eisai PDGFRα/β Multikinase Antagonists Product Portfolio
  18. 7.3.5 Eisai Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis PDGFRα/β Multikinase Antagonists Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Eli Lilly
  26. 7.5.1 Eli Lilly Company Information
  27. 7.5.2 Eli Lilly Business Overview
  28. 7.5.3 Eli Lilly PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Eli Lilly PDGFRα/β Multikinase Antagonists Product Portfolio
  30. 7.5.5 Eli Lilly Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer PDGFRα/β Multikinase Antagonists Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 GSK
  38. 7.7.1 GSK Company Information
  39. 7.7.2 GSK Business Overview
  40. 7.7.3 GSK PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GSK PDGFRα/β Multikinase Antagonists Product Portfolio
  42. 7.7.5 GSK Recent Developments
  43. 7.8 Boehringer Ingelheim
  44. 7.8.1 Boehringer Ingelheim Company Information
  45. 7.8.2 Boehringer Ingelheim Business Overview
  46. 7.8.3 Boehringer Ingelheim PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Boehringer Ingelheim PDGFRα/β Multikinase Antagonists Product Portfolio
  48. 7.8.5 Boehringer Ingelheim Recent Developments
  49. 7.9 Bayer
  50. 7.9.1 Bayer Company Information
  51. 7.9.2 Bayer Business Overview
  52. 7.9.3 Bayer PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bayer PDGFRα/β Multikinase Antagonists Product Portfolio
  54. 7.9.5 Bayer Recent Developments
  55. 7.10 Bristol-Myers Squibb
  56. 7.10.1 Bristol-Myers Squibb Company Information
  57. 7.10.2 Bristol-Myers Squibb Business Overview
  58. 7.10.3 Bristol-Myers Squibb PDGFRα/β Multikinase Antagonists Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bristol-Myers Squibb PDGFRα/β Multikinase Antagonists Product Portfolio
  60. 7.10.5 Bristol-Myers Squibb Recent Developments
8 North America
  1. 8.1 North America PDGFRα/β Multikinase Antagonists Revenue (2021-2032)
  2. 8.2 North America PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2032)
  3. 8.2.1 North America PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2026)
  4. 8.2.2 North America PDGFRα/β Multikinase Antagonists Revenue by Type (2027-2032)
  5. 8.3 North America PDGFRα/β Multikinase Antagonists Revenue Share by Type (2021-2032)
  6. 8.4 North America PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2032)
  7. 8.4.1 North America PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2026)
  8. 8.4.2 North America PDGFRα/β Multikinase Antagonists Revenue by Application (2027-2032)
  9. 8.5 North America PDGFRα/β Multikinase Antagonists Revenue Share by Application (2021-2032)
  10. 8.6 North America PDGFRα/β Multikinase Antagonists Revenue by Country
  11. 8.6.1 North America PDGFRα/β Multikinase Antagonists Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America PDGFRα/β Multikinase Antagonists Revenue by Country (2021-2026)
  13. 8.6.3 North America PDGFRα/β Multikinase Antagonists Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe PDGFRα/β Multikinase Antagonists Revenue (2021-2032)
  2. 9.2 Europe PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2032)
  3. 9.2.1 Europe PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2026)
  4. 9.2.2 Europe PDGFRα/β Multikinase Antagonists Revenue by Type (2027-2032)
  5. 9.3 Europe PDGFRα/β Multikinase Antagonists Revenue Share by Type (2021-2032)
  6. 9.4 Europe PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2032)
  7. 9.4.1 Europe PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2026)
  8. 9.4.2 Europe PDGFRα/β Multikinase Antagonists Revenue by Application (2027-2032)
  9. 9.5 Europe PDGFRα/β Multikinase Antagonists Revenue Share by Application (2021-2032)
  10. 9.6 Europe PDGFRα/β Multikinase Antagonists Revenue by Country
  11. 9.6.1 Europe PDGFRα/β Multikinase Antagonists Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe PDGFRα/β Multikinase Antagonists Revenue by Country (2021-2026)
  13. 9.6.3 Europe PDGFRα/β Multikinase Antagonists Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China PDGFRα/β Multikinase Antagonists Revenue (2021-2032)
  2. 10.2 China PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2032)
  3. 10.2.1 China PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2026)
  4. 10.2.2 China PDGFRα/β Multikinase Antagonists Revenue by Type (2027-2032)
  5. 10.3 China PDGFRα/β Multikinase Antagonists Revenue Share by Type (2021-2032)
  6. 10.4 China PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2032)
  7. 10.4.1 China PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2026)
  8. 10.4.2 China PDGFRα/β Multikinase Antagonists Revenue by Application (2027-2032)
  9. 10.5 China PDGFRα/β Multikinase Antagonists Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia PDGFRα/β Multikinase Antagonists Revenue (2021-2032)
  2. 11.2 Asia PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2032)
  3. 11.2.1 Asia PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2026)
  4. 11.2.2 Asia PDGFRα/β Multikinase Antagonists Revenue by Type (2027-2032)
  5. 11.3 Asia PDGFRα/β Multikinase Antagonists Revenue Share by Type (2021-2032)
  6. 11.4 Asia PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2032)
  7. 11.4.1 Asia PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2026)
  8. 11.4.2 Asia PDGFRα/β Multikinase Antagonists Revenue by Application (2027-2032)
  9. 11.5 Asia PDGFRα/β Multikinase Antagonists Revenue Share by Application (2021-2032)
  10. 11.6 Asia PDGFRα/β Multikinase Antagonists Revenue by Country
  11. 11.6.1 Asia PDGFRα/β Multikinase Antagonists Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia PDGFRα/β Multikinase Antagonists Revenue by Country (2021-2026)
  13. 11.6.3 Asia PDGFRα/β Multikinase Antagonists Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA PDGFRα/β Multikinase Antagonists Revenue (2021-2032)
  2. 12.2 SAMEA PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA PDGFRα/β Multikinase Antagonists Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA PDGFRα/β Multikinase Antagonists Revenue by Type (2027-2032)
  5. 12.3 SAMEA PDGFRα/β Multikinase Antagonists Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA PDGFRα/β Multikinase Antagonists Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA PDGFRα/β Multikinase Antagonists Revenue by Application (2027-2032)
  9. 12.5 SAMEA PDGFRα/β Multikinase Antagonists Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA PDGFRα/β Multikinase Antagonists Revenue by Country
  11. 12.6.1 SAMEA PDGFRα/β Multikinase Antagonists Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA PDGFRα/β Multikinase Antagonists Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA PDGFRα/β Multikinase Antagonists Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst